文献速递贫血与红细胞疾病

PUM1介导人胎儿血红蛋白的转录后调控

PUM1 mediates the posttranscriptional regulation of human fetal hemoglobin.
PubMed 文献 · Blood Adv · 2022-01-01

本研究鉴定RNA结合蛋白PUM1为β-珠蛋白转换的直接转录后调控因子,其表达受EKLF/KLF1调控,在红系分化中达峰,结合γ-珠蛋白mRNA并降低其稳定性与翻译效率。敲低PUM1使人红系细胞胎儿血红蛋白增至约22%而不影响β-珠蛋白水平,且不限制红系分化进程。一例携带PUM1 RNA结合域新发杂合突变的个体无贫血而HbF升高,支持PUM1介导的转录后调控在人血红蛋白转换中的关键作用。

要点

  • PUM1受EKLF/KLF1调控,在红系分化中达峰,结合γ-珠蛋白mRNA。
  • PUM1降低HBG1 mRNA稳定性与翻译效率,减少γ-珠蛋白蛋白水平。
  • 敲低PUM1使人红系细胞HbF增至约22%,不影响β-珠蛋白且不限制红系分化。

核心结论

  • PUM1是β-珠蛋白转换的直接转录后调控因子,敲低PUM1可使人红系细胞HbF增至约22%且不限制红系分化,作者认为这为镰状细胞贫血和β-地中海贫血提供了可能安全有效的治疗策略。
  • 一例携带PUM1 RNA结合域新发杂合突变(p.(His1090Profs∗16); c.3267_3270delTCAC)的个体无贫血而HbF升高,提示PUM1介导的转录后调控是人血红蛋白转换中的关键因素。

研究设计与样本

  • 基础研究,在人红系细胞中鉴定PUM1为β-珠蛋白转换的转录后调控因子,并报告一例携带PUM1新发杂合突变的个体。

主要发现

  • PUM1表达受红系主转录因子EKLF/KLF1调控,在红系分化中达峰,结合γ-珠蛋白mRNA,降低γ-珠蛋白(HBG1)mRNA稳定性与翻译效率,最终降低γ-珠蛋白蛋白水平。
  • 敲低PUM1使人红系细胞胎儿血红蛋白(HbF)增至约22%,而不影响β-珠蛋白水平。
  • 靶向PUM1不限制红系分化进程。
  • 一例携带PUM1 RNA结合域新发杂合突变(p.(His1090Profs∗16); c.3267_3270delTCAC)的个体无贫血而HbF升高。

临床怎么用

  • 作者认为靶向PUM1为镰状细胞贫血和β-地中海贫血提供了可能安全有效的治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The fetal-to-adult hemoglobin switching at about the time of birth involves a shift in expression from γ-globin to β-globin in erythroid cells. Effective re-expression of fetal γ-globin can ameliorate sickle cell anemia and β-thalassemia. Despite the physiological and clinical relevance of this switch, its posttranscriptional regulation is poorly understood. Here, we identify Pumilo 1 (PUM1), an RNA-binding protein with no previously reported functions in erythropoiesis, as a direct posttranscriptional regulator of β-globin switching. PUM1, whose expression is regulated by the erythroid master transcription factor erythroid Krüppel-like factor (EKLF/KLF1), peaks during erythroid differentiation, binds γ-globin messenger RNA (mRNA), and reduces γ-globin (HBG1) mRNA stability and translational efficiency, which culminates in reduced γ-globin protein levels. Knockdown of PUM1 leads to a robust increase in fetal hemoglobin (∼22% HbF) without affecting β-globin levels in human erythroid cells. Importantly, targeting PUM1 does not limit the progression of erythropoiesis, which provides a potentially safe and effective treatment strategy for sickle cell anemia and β-thalassemia. In support of this idea, we report elevated levels of HbF in the absence of anemia in an individual with a novel heterozygous PUM1 mutation in the RNA-binding domain (p.(His1090Profs∗16); c.3267_3270delTCAC), which suggests that PUM1-mediated posttranscriptional regulation is a critical player during human hemoglobin switching.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Elagooz R, Dhara AR, Gott RM, et al. PUM1 mediates the posttranscriptional regulation of human fetal hemoglobin. Blood Adv. 2022. PMID: 35667093. doi:10.1182/bloodadvances.2021006730

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。